Keyphrases
COVID-19
100%
Growth Arrest-specific Gene 6 (Gas6)
43%
Rheumatoid Arthritis
31%
Vitamin D
29%
Systemic Sclerosis
28%
Bronchoalveolar Lavage
21%
Emergency Department
19%
Tyro3
19%
SARS-CoV-2 Infection
18%
Hospitalization
18%
Hospitalized Patients
17%
Liver Stiffness
17%
Plasma Parameters
16%
COVID-19 Patients
16%
Italy
16%
Connective Tissue Disease
15%
Hospitalized COVID-19 Patients
15%
Pulmonary Arterial Hypertension
14%
Clinical Outcomes
14%
Osteopontin
13%
Fibrosis
12%
Type 2 Diabetes Mellitus (T2DM)
12%
Moderate to Severe
12%
Plasma Concentration
12%
Multiple Sclerosis
12%
Depressive Symptoms
12%
Italian Cohort
12%
Comorbidity
12%
Hospital Discharge
11%
Lung
11%
Chronic Liver Disease
11%
Sepsis
11%
REPOSI
11%
Insulin Resistance
10%
Red Cell Distribution Width
10%
Inflammation
10%
Tocilizumab
10%
Non-alcoholic Fatty Liver Disease (NAFLD)
10%
Idiopathic Pulmonary Fibrosis
9%
Hepatitis C Virus
9%
Tyrosine Kinase Receptor
9%
Cerebrospinal Fluid
9%
Odds Ratio
9%
Diabetes
9%
MerTK
9%
Mortality Prediction
9%
HSD17B13
9%
Rituximab
9%
Polymyalgia Rheumatica
9%
Calcitonin Gene-related Peptide
9%
Medicine and Dentistry
COVID-19
66%
Biological Marker
30%
Sequela
28%
Infection
27%
Severe Acute Respiratory Syndrome Coronavirus 2
25%
Diseases
22%
Fibrosis
19%
Growth Disorder
19%
Lung Lavage
18%
Rheumatoid Arthritis
15%
Inflammatory Arthritis
15%
Systemic Scleroderma
15%
Emergency Department
14%
Liver Fibrosis
11%
Chronic Liver Disease
10%
Receptor
10%
Liver Cirrhosis
10%
Tocilizumab
9%
Lung
9%
Internal Medicine
9%
Idiopathic Pulmonary Fibrosis
9%
Disease Course
9%
Postcovid Syndrome
9%
Adverse Outcome
9%
Computer Assisted Tomography
9%
Prevalence
8%
Pulmonary Hypertension
8%
Connective Tissue Disease
8%
Prospective Cohort Study
8%
DLCO
8%
Transient Elastography
8%
Rituximab
8%
Coronavirinae
8%
Nasopharyngeal Swab
7%
Hepatitis C Virus
7%
Chronic Hepatitis C
7%
Vitamin D
7%
Comorbidity
6%
Cohort Analysis
6%
Hepatocellular Carcinoma
6%
Osteopontin
6%
Systematic Review
6%
Cardiovascular System
6%
Fatty Liver
6%
Odds Ratio
6%
Growth Arrest Specific Protein 6
6%
Interstitial Lung Disease
6%
Rheumatic Disease
6%
Congestive Heart Failure
6%
Hepatitis C
6%
Pharmacology, Toxicology and Pharmaceutical Science
Diseases
57%
Coronavirinae
39%
Vitamin D
34%
Biological Marker
27%
SARS Coronavirus
26%
Growth Disorder
25%
Infection
24%
Systemic Sclerosis
21%
Rheumatoid Arthritis
15%
Inflammatory Arthritis
15%
Comorbidity
15%
Receptor
15%
Fibrosis
13%
Inflammation
12%
Disease Course
12%
Liver Fibrosis
11%
Cholecalciferol
10%
Connective Tissue Disease
9%
Chronic Obstructive Lung Disease
9%
Adverse Outcome
9%
Antiviral Drug
8%
Pulmonary Hypertension
8%
Prospective Cohort Study
8%
Diabetes Mellitus
8%
Cohort Study
8%
Hypovitaminosis D
8%
Hepatitis C Virus
7%
Insulin Resistance
7%
Non Insulin Dependent Diabetes Mellitus
7%
Observational Study
7%
Lower Respiratory Tract Infection
7%
Cytokine
7%
Prevalence
6%
Osteopontin
6%
Interferon
6%
Fibrosing Alveolitis
6%
Hepatitis C
6%
Rheumatic Disease
6%
Antivirus Agent
6%
Clinical Feature
6%
Nonalcoholic Fatty Liver
6%
Model Selection
6%
Hospital Mortality
6%
Depressive Disorder
6%
Malignant Neoplasm
5%
Dipeptidyl Carboxypeptidase Inhibitor
5%
Interstitial Lung Disease
5%
Liver Cirrhosis
5%
